OS Therapies is at the forefront of developing innovative cancer treatments, particularly focusing on osteosarcoma and other solid tumors. Their primary technologies include the OST-HER2 LM Vaccine and OST-tADC (Tunable Antibody-Drug Conjugates). The OST-HER2 LM Vaccine is designed to target HER2-positive cancers, such as osteosarcoma and breast cancer, by activating the immune system to enhance the body's ability to fight cancer. This vaccine trains T cells to identify and destroy cancer cells, creating a continuous immune response that can potentially prevent recurrences of the disease. The mechanism involves T cells directly attacking cancer cells, which exposes new targets for further immune activation.

In addition to the vaccine, OS Therapies employs the OST-tADC technology, which utilizes targeted antibody-drug conjugates to improve the efficacy and safety of cancer treatments. These conjugates selectively bind to specific receptors on cancer cells, allowing for the internalization of a toxin payload that is released in the acidic environment of the tumor. This targeted approach not only enhances the therapeutic effect on the cancer cells but also minimizes damage to healthy tissues. The combination of these advanced technologies positions OS Therapies to make significant strides in the treatment of various cancers, including ovarian, lung, pancreatic, and esophageal cancers, alongside their primary focus on osteosarcoma.

United States

OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors.

Cancer

OS Therapies

Osteosarcoma

"<p class=""font_7""> OST-HER2, a biologic therapeutic candidate, is a Lm (Listeria monocytogenes) vector-based off-the-shelf immunotherapeutic vaccine designed to prevent metastasis, delay recurrence, and increase overall survival in patients with Osteosarcoma.</p>

OS Therapies

Company Details